Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Diamondcutter who wrote (6386)	4/12/1999 3:43:00 PM
From: Mkilloran	Read Replies (1) \| Respond to of 7041

Diamondcutter...looks like Zona won't make much in 1999 at all if it is approved late in the 4th qtr.

To: Diamondcutter who wrote (6386)	4/12/1999 4:12:00 PM
From: Linda Kaplan	Read Replies (1) \| Respond to of 7041

You edited out all the negatives! However, they did seem to think that Vasomax would not be included in the June meeting and the fact is that Vasomax hasn't been SCHEDULED for the JUNE meeting, so it's gotta go back to Sept, if it has to be reviewed in a meeting, and it does seem that Oppenheimer is convinced that it MUST be reviewed in a panel meeting prior to approval (or NON approval). I never mentioned whether ZONA would be expected to be present at such a panel meeting or not (seems to me that is irrelevant), but I did say that Vasomax is not scheduled to be considered at the June panel meeting. It is interesting that additional studies did have to be prepared. It's also interesting that Oppenheimer was told enough about the results to be convinced they were favorable. I would expect that Oppenheimer was not given the full story on that; Zonagen so rarely seems to provide the full story. Of course they shouldn't be providing ANY story to anyone but the FDA these days, should they? Linda